Stay updated with breaking news from Christopher Posner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Cara Therapeutics’ (NASDAQ:CARA) lead candidate KORSUVA (difelikefalin) ...
Wall Street analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) to report $15.33 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Cara Therapeutics’ earnings, with the lowest sales estimate coming in at $7.50 million and the highest estimate coming in at $22.28 million. The company […]